PEGylated thymosin β4 is a thiol-site-specific prodrug treating myocardial infarction in vivo. — VialBase Research

Summary

This preclinical study engineered a longer-acting form of thymosin β4 (Tβ4) to treat myocardial infarction. The authors built a modified prokaryotic expression system to make recombinant Tβ4 (rTβ4), then applied single thiol-site-specific PEGylation to produce the prodrug PEG-rTβ4, characterizing it by MALDI-TOF mass spectrometry, differential scanning calorimetry, and thermal gravimetric analysis. In vivo, the long-circulating PEG-rTβ4 relieved myocardial remodeling, restored cardiac function, promoted neoangiogenesis, and inhibited apoptosis through the Akt/Bcl-2/caspase-3 pathway. Tβ4 is the full-length parent peptide of the synthetic fragment TB-500.

Key Findings

• A modified prokaryotic expression system was developed to produce recombinant Tβ4 (rTβ4), which was then converted to the prodrug PEG-rTβ4 by single, thiol-site-specific PEGylation.
• PEG-rTβ4 was identified and its thermodynamic properties assessed using MALDI-TOF mass spectrometry, a differential scanning calorimeter, and a thermal gravimetric analyzer, with the data indicating superiority for treating myocardial infarction.
• In vivo, long-circulating PEG-rTβ4 significantly relieved myocardial remodeling, restored cardiac function, promoted neoangiogenesis, and inhibited apoptosis via the Akt/Bcl-2/caspase-3 pathway.
• The authors note that despite more than 10 years of clinical trials (ulcers, dry eye syndrome, acute MI) no Tβ4 drug has been approved, citing druggability barriers of supply, purity, verified efficacy/safety, half-life, and shelf-life, and conclude PEG-rTβ4 is a better drug-development choice.

Relevance to TB-500

TB-500 is the synthetic fragment of thymosin β4 (Tβ4), so the full-length protein’s translational hurdles and cardiac-repair activity are directly informative here. This study addresses a core druggability problem for any Tβ4-based therapeutic — short circulating half-life — by showing that site-specific PEGylation yields a long-circulating prodrug that still delivers Tβ4’s repair signals, restoring cardiac function and driving neoangiogenesis after infarction. The finding reinforces the cardiac and angiogenic repair biology often cited for Tβ4-derived peptides, while also underscoring that the parent protein itself remains preclinical and unapproved. As an engineering and animal-efficacy report, it speaks to formulation strategy and mechanism rather than to any validated human use of TB-500 or of Tβ4 more broadly, a theme it shares with translational reviews of related repair peptides such as BPC-157.

Citation

Peng H, Chai Y, Gong C, et al. PEGylated thymosin β4 is a thiol-site-specific prodrug treating myocardial infarction in vivo. Bioengineering & translational medicine. 2026. doi:10.1002/btm2.70144.

See Also

• Parent compound: TB-500
• BPC-157